These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34009241)

  • 1. Efficacy of subcutaneous tocilizumab in a patient with severe gout refractory to anakinra.
    Calvo-Aranda E; Sanchez-Aranda FM
    Rheumatology (Oxford); 2021 Nov; 60(11):e375-e377. PubMed ID: 34009241
    [No Abstract]   [Full Text] [Related]  

  • 2. IL-1 inhibition with anakinra in a patient with refractory gout.
    Singh D; Huston KK
    J Clin Rheumatol; 2009 Oct; 15(7):366. PubMed ID: 20009976
    [No Abstract]   [Full Text] [Related]  

  • 3. Anakinra's efficacy is variable in refractory gout: report of ten cases.
    Chen K; Fields T; Mancuso CA; Bass AR; Vasanth L
    Semin Arthritis Rheum; 2010 Dec; 40(3):210-4. PubMed ID: 20494407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy but side effects of anakinra therapy for chronic refractory gout in a renal transplant recipient with preterminal chronic renal failure.
    Direz G; Noël N; Guyot C; Toupance O; Salmon JH; Eschard JP
    Joint Bone Spine; 2012 Dec; 79(6):631. PubMed ID: 22841588
    [No Abstract]   [Full Text] [Related]  

  • 5. Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout.
    Tran AP; Edelman J
    Int J Rheum Dis; 2011 Aug; 14(3):e33-7. PubMed ID: 21816011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
    Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
    Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of anti Interleukin-1 β monoclonal antibody in the treatment of recurrent pericarditis in two children.
    Signa S; D'Alessandro M; Consolini R; Miniaci A; Bustaffa M; Longo C; Tosca MA; Bizzi M; Caorsi R; Mendonça LO; Pession A; Ravelli A; Gattorno M
    Pediatr Rheumatol Online J; 2020 Jun; 18(1):51. PubMed ID: 32546242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Anakinra in Acute Crystalline Diseases: A Retrospective Study Comparing a University Hospital with a Veterans Affairs Medical Center.
    Desmarais J; Chu CQ
    J Rheumatol; 2019 Jul; 46(7):748-750. PubMed ID: 30442822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switch from anakinra to canakinumab in a severe case of CINCA syndrome.
    Rigante D; Verrecchia E; Falsini B; Manna R
    Int J Rheum Dis; 2016 Dec; 19(12):1354-1356. PubMed ID: 26585548
    [No Abstract]   [Full Text] [Related]  

  • 10. [Wells' cellulitis and bacterial necrotizing cellulitis induced by anakinra].
    Livory M; Wechsler J; Revuz J; Bagot M; Chevalier X; Poszepczynska-Guigné E
    Ann Dermatol Venereol; 2008 Dec; 135(12):839-42. PubMed ID: 19084694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anakinra for the treatment of rheumatoid arthritis: a safety evaluation.
    Ramírez J; Cañete JD
    Expert Opin Drug Saf; 2018 Jul; 17(7):727-732. PubMed ID: 29883212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case report of a novel compound heterozygous mutation in a Brazilian patient with deficiency of Interleukin-1 receptor antagonist (DIRA).
    Mendonça LO; Grossi A; Caroli F; de Oliveira RA; Kalil J; Castro FFM; Pontillo A; Ceccherini I; Barros MAMT; Gattorno M
    Pediatr Rheumatol Online J; 2020 Aug; 18(1):67. PubMed ID: 32819369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.
    Aomar-Millán IF; Salvatierra J; Torres-Parejo Ú; Faro-Miguez N; Callejas-Rubio JL; Ceballos-Torres Á; Cruces-Moreno MT; Gómez-Jiménez FJ; Hernández-Quero J; Anguita-Santos F
    Intern Emerg Med; 2021 Jun; 16(4):843-852. PubMed ID: 33400157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of familial Mediterranean fever with anakinra in patients unresponsive to colchicine.
    Pecher AC; Igney-Oertel A; Kanz L; Henes J
    Scand J Rheumatol; 2017 Sep; 46(5):407-409. PubMed ID: 28097903
    [No Abstract]   [Full Text] [Related]  

  • 15. An effusion of blood and phlegmon secondary to anakinra injection.
    Ortiz AE; Fulwider CM; Wu JJ
    Cutis; 2010 Mar; 85(3):130-1. PubMed ID: 20408510
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis.
    Moltó A; Ea HK; Richette P; Bardin T; Lioté F
    Joint Bone Spine; 2012 Dec; 79(6):621-3. PubMed ID: 22658375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.
    Emery P; Keystone E; Tony HP; Cantagrel A; van Vollenhoven R; Sanchez A; Alecock E; Lee J; Kremer J
    Ann Rheum Dis; 2008 Nov; 67(11):1516-23. PubMed ID: 18625622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.
    Sundy JS; Schumacher HR; Kivitz A; Weinstein SP; Wu R; King-Davis S; Evans RR
    J Rheumatol; 2014 Aug; 41(8):1703-11. PubMed ID: 25028379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acitretin- and tumor necrosis factor inhibitor-resistant acrodermatitis continua of hallopeau responsive to the interleukin 1 receptor antagonist anakinra.
    Lutz V; Lipsker D
    Arch Dermatol; 2012 Mar; 148(3):297-9. PubMed ID: 22431771
    [No Abstract]   [Full Text] [Related]  

  • 20. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.
    Huizinga TW; Fleischmann RM; Jasson M; Radin AR; van Adelsberg J; Fiore S; Huang X; Yancopoulos GD; Stahl N; Genovese MC
    Ann Rheum Dis; 2014 Sep; 73(9):1626-34. PubMed ID: 24297381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.